Search

Corvus Pharmaceuticals Inc

Gesloten

12.93 -0.92

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.43

Max

13.11

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+125.02% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-21M

1.1B

Vorige openingsprijs

13.85

Vorige sluitingsprijs

12.93

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 sep 2026, 23:56 UTC

Akebia Therapeutics Inc shares are higher in after-market trading. Broader market sentiment is affected by a sharp decline in the NY Empire State Manufacturing Index.

15 sep 2026, 23:56 UTC

Fastly Inc. shares declined after-market, influenced by negative sentiment from the NY Empire State Manufacturing Index's sharp fall. The stock settled lower after a brief recovery.

15 sep 2026, 23:56 UTC

News

Lululemon Athletica shares are lower in after-market hours amid an investigation into potential securities law violations following a revenue guidance cut.

15 sep 2026, 23:56 UTC

eHealth Inc. shares were little changed in after-market hours. Broader market sentiment weakened following a significant decline in the NY Empire State Manufacturing Index.

15 sep 2026, 23:56 UTC

Maxlinear Inc shares are lower in after-market hours, pressured by a sharp decline in the NY Empire State Manufacturing Index, raising economic concerns.

15 sep 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading amid negative sentiment following a sharp decline in the NY Empire State Manufacturing Index.

15 sep 2026, 23:56 UTC

Textron Inc shares are higher in after-market trading, reaching a peak gain following the NY Empire State Manufacturing Index's sharp decline to 7.6 for September.

15 sep 2026, 23:56 UTC

Bandwidth Inc. shares declined in after-market hours, reflecting negative sentiment tied to a sharp drop in the NY Empire State Manufacturing Index.

15 sep 2026, 23:52 UTC

Japan's August trade deficit hits -1052.6 billion yen amid ongoing economic challenges and weak yen concerns, raising questions on future monetary policy.

15 sep 2026, 23:52 UTC

Japan's Exports Expected to Rise 0.182% YoY Amid Cautious Optimism in Global Trade Dynamics

15 sep 2026, 23:52 UTC

Japan's Machinery Orders Expected to Decline by 2.8% in September, Raising Concerns Over Capital Spending and Business Investment

15 sep 2026, 23:52 UTC

US Business Inventories MoM Data Release on September 16 Expected to Show Modest 0.3% Increase Amid Inflation and Interest Rate Concerns.

15 sep 2026, 23:52 UTC

Brazil's Central Bank to announce interest rate decisions on September 21, amid global focus on central bank policies and inflation concerns.

15 sep 2026, 23:52 UTC

NAHB Housing Market Index for September 2026 Expected at 34.0 Amid Ongoing Builder Confidence Concerns and Slowing Home Construction

15 sep 2026, 23:52 UTC

U.S. Industrial Production Expected to Rise 0.3% in September Amid Mixed Economic Signals and Global Concerns

15 sep 2026, 23:51 UTC

Innovative Industrial Properties Inc shares are higher in after-market hours, though no specific company news was identified to explain the movement.

15 sep 2026, 23:51 UTC

Box Inc shares are higher in after-market hours, continuing a trend of higher closes over the last three sessions. No specific news was identified.

15 sep 2026, 23:51 UTC

Correlated Moves

Shares of Sunrun Inc. declined in after-market trading, diverging from recent trends amid mixed economic data and rising U.S. crude oil inventories.

15 sep 2026, 23:51 UTC

Progressive Corp shares declined during after-market hours, reaching a low of -0.61%. No specific news was identified to explain the price movement.

15 sep 2026, 23:51 UTC

Correlated Moves

Ross Stores Inc shares are higher in after-market trading, reflecting positive sentiment linked to TJX Companies Inc's performance amid increased after-hours activity.

15 sep 2026, 23:51 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. This marks a shift from recent trends.

15 sep 2026, 23:51 UTC

Under Armour Inc shares are lower in after-market trading, continuing declines amid inflation concerns linked to rising U.S. crude oil inventories.

15 sep 2026, 23:51 UTC

Minerals Technologies Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

15 sep 2026, 23:51 UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

15 sep 2026, 23:51 UTC

Correlated Moves

Raymond James Financial shares are higher in after-market trading, aligning with Bank of America's performance despite mixed broader market sentiment.

15 sep 2026, 23:51 UTC

T-Mobile US Inc shares are higher in after-market hours, continuing a recent upward trend from earlier lows. No specific news was identified for the movement.

15 sep 2026, 23:46 UTC

Insight Enterprises Inc shares are higher in after-market trading, advancing slightly since Tuesday's close. The stock is positioned above its 20-day moving average.

15 sep 2026, 23:46 UTC

California Water Service Group shares were roughly flat in after-market hours, remaining about 3.74% below their 20-day moving average.

15 sep 2026, 23:46 UTC

LeMaitre Vascular Inc. shares are higher in after-market trading, moving within a narrow range since Tuesday's close and remaining near the lower end of their monthly range.

15 sep 2026, 23:46 UTC

Essential Utilities Inc shares are higher in after-market hours, remaining near the upper end of their one-month trading range. No specific news was identified.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

125.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  125.02%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat